The key catalyst remains the PRECISE-AD 12-month unblinded topline data in Q1 2027, which will provide the first look at PMN310's efficacy and safety versus placebo. Cash runway through 2027 removes near-term financing risk. Monitor the CTAD conference (Nov 16-19, 2026) for any additional interim data presentations.
Drug in focus
PMN drug pipeline →PMN310
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 1b
- Time to market
- Years away — Phase 1b enrollment complete, but Phase 2/3 trials, if initiated, would take multiple years. Best-case earliest approval likely 2029+.
- Next catalyst
- None dated
What to watchThe Phase 1b PRECISE-AD interim analysis (blinded 6-month biomarker data) is the critical near-term catalyst, expected within weeks. Positive biomarker signals (Aβ oligomer reduction, pTau) could send the stock sharply higher given the low float and ~$12.80 share price vs. ~$32 mean analyst target. However, a Phase 1b readout is not de-risking enough to guarantee Phase 2/3 success, and the competitive Alzheimer's landscape is crowded with approved drugs (lecanemab, donanemab).
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 13 $3.29entry
- T+1 · 20h ago +0.61%α +2.52% · $3.31
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ProMIS Neurosciences reported Q3 2026 net loss of $8.2M ($0.89 per share) and cash of $44.1M, reaffirming on-track unblinded 12-month topline data from the PRECISE-AD Phase 1b trial in Q1 2027. The filing is a routine quarterly update for a pre-revenue clinical-stage biotech with no consensus EPS or revenue to compare against.
Key Financial Metrics
Key Facts
- Cash of $44.1M as of September 30, 2026, expected to fund operations through 2027
- Net loss of $8.2M for Q3 2026 versus $11.6M in Q3 2025
- R&D expenses decreased 32% to $6.7M due to PRECISE-AD nearing completion
- PRECISE-AD unblinded 12-month topline data anticipated in Q1 2027
- Ivana Rubino appointed Chief Commercial Officer effective October 5, 2026
- Blinded 6-month interim data showed no ARIA-E, 4.4% ARIA-H (mild, asymptomatic), and biomarker decreases in pooled population
Financial Impact
Net loss $8.2M; cash burn rate approximately $2.7M per month based on $44.1M cash and expected runway through 2027
Risk Factors
- Interim blinded data may not predict final unblinded results
- Clinical-stage biotech with no approved products or revenue
- Accumulated deficit of $158.5M as of September 30, 2026
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-126260 |
| Document: pmn-20261112x8k.htm | 0001104659-26-126260 |
| Document: 0001104659-26-126260-index-headers.html | 0001104659-26-126260 |
| Document: 0001104659-26-126260-index.html | 0001104659-26-126260 |
| Document: 0001104659-26-126260.txt | 0001104659-26-126260 |
| 8-K Data (Synthetic) | 0001104659-26-126260 |
Track record
16 reports on PMN
4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +43.16% at T+60 after the Mar 18, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 17, 2026today Press Release Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.25 Now $3.31 +1.85% settles Nov 18
- Nov 12, 20264d ago 8-K Neutral 4/10 Viewing Entry $3.29 to $3.31 Now $3.31 +0.61% ▲ +0.61% +2.52% vs SPY
- Nov 12, 20264d ago SC 13G Neutral 4/10 Entry $3.48 to $3.29 Now $3.31 −4.89% ▼ −5.46% −5.10% vs SPY
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $3.48 to $3.29 Now $3.31 −4.89% ▼ −5.46% −5.10% vs SPY
- Nov 6, 202610d ago Insider Cluster Bullish 4/10 Entry $4.16 to $4.05 Now $3.31 −20.43% ▼ −2.64% −5.01% vs SPY
- Nov 5, 202611d ago Press Release Neutral 2/10 Entry $3.65 to $4.16 Now $3.31 −9.32% ▲ +13.97% +13.66% vs SPY
- Oct 6, 20265w ago 3 Neutral 2/10 Entry $9.12 to $9.15 Now $3.31 −63.71% ▲ +0.33% +0.75% vs SPY
- Oct 6, 20265w ago Press Release Neutral 3/10 Entry $9.21 to $9.12 Now $3.31 −64.06% ▼ −0.98% −0.74% vs SPY
- Sep 1, 202610w ago Press Release Neutral 3/10 Entry $13.35 to $13.98 Now $3.31 −75.21% ▲ +4.68% +4.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers